myADA
Anti-drug antibody risk prediction - Next-generation in-silico ADA risk prediction
myADA delivers accurate, scalable, biologically grounded anti-drug antibody (ADA) risk prediction. It is a next-generation, in-silico tool centered on advanced MHC class II epitope immunogenicity modeling, powered by our neoIM immunogenicity algorithm. By accurately identifying CD4+ T-cell epitopes capable of initiating T-cell-dependent ADA responses, myADA supports proactive, design-stage control of biologic immunogenicity to accelerate antibody design and development.
What myADA delivers
ADA risk prediction has a turnaround time of one week:
- High-risk candidate prediction: flagging and deprioritization of drug candidates with high likelihood of eliciting anti-drug antibodies
- Immunogenicity hotspot identification: identification of high-impact immunogenic epitope clusters across the antibody sequence
- Immunogenic hotspot re-engineering: re-engineering based on protein regions likely to be immunogenic in large populations, identification of MHC I/II immunogenic epitopes, and isolated immunogenicity hotspots
- Population-level impact assessment: interpolation of immunogenicity impact across the whole population
- Humanness profiling: quantification of human-like antibody sequences
- Similarity comparison to known antibodies: screening against a database of known antibodies for structural and functional similarity
- Clinical benchmarking: each candidate is scored as a percentile against more than 100 clinically tested antibodies with documented ADA outcomes, annotated from more than 3,000 trial arms across over 750 trials
Inspect ADA risk before wet-lab work
The hosted myADA application maps MHC class II immunogenicity hotspots across the sequence, ranks candidates against a clinically annotated antibody reference set, and supports lead selection and sequence optimization.
What is myADA?
myADA is myNEO's in-silico anti-drug antibody risk-assessment platform, available at myada.myneotx.com (opens in a new tab). It identifies MHC class II epitopes with the potential to induce CD4+ T-cell responses, maps immunogenicity hotspots across the sequence, and interprets these findings in the context of the biologic's mechanism of action to estimate clinical ADA risk.
How does myADA help antibody development?
myADA ranks candidates by predicted ADA risk, identifies immunogenicity hotspots for targeted re-engineering, profiles humanness and similarity to known antibodies, and estimates population-level impact across HLA backgrounds. These outputs support lead selection and sequence optimization before wet-lab work.
What is myADA benchmarked against?
Every candidate is scored against a reference database of more than 100 clinically tested antibodies with documented real-world anti-drug antibody outcomes, annotated from more than 3,000 clinical trial arms across over 750 trials. A candidate's score is reported as a percentile within that clinically anchored distribution.
What is the turnaround time for myADA?
ADA risk prediction with myADA has a turnaround time of one week. Required inputs and deliverables are confirmed for each project.
Is scientific documentation available for myADA?
Yes. The myADA technology paper describes the model, its clinical reference database, and its benchmarking results. The paper is also available through the publications library.